RankAlpha logo
Back to Rankings

SMMT

Summit TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The April 30 company update kept the core ivonescimab timeline intact: ASCO OS data on May 31, HARMONi-3 squamous final PFS still in 2H 2026, and the November 14, 2026 PDUFA unchanged. The interim HARMONi-3 review did not raise safety concerns, which preserves the lead-program thesis [#8-K-2026-04-30].
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-07-23 · AMC.
What can break
Lead-asset concentration remains extreme; ivonescimab drives the thesis, so weak ASCO, Phase III, or FDA outcomes could re-rate the equity sharply lower.
Momentum
13
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $24.00 · Bear $9.00
Earnings
2026-07-23 · AMC
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $29.84
Why
Momentum13 · Δ7d +1.1
Value41 · Δ7d -0.1
Sentiment63 · Δ7d +7.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
13
26% active weight
Current posture
7d trendFlat
Δ7d
+1.1
Δ21d
+5.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
63
34% active weight
Current posture
7d trendImproving
Δ7d
+7.1
Δ21d
-0.2
Why this grade

Composite grade D. Momentum 12.6 / Value 41.1 / Sentiment 62.9

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$10.72B
Beta
-1.44
Shares Out
776.16M
P/E (TTM) · Derived
-9.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-27.05
Rev YoY
-100.0%
EPS YoY
+186.7%
Gross Margin
+97.2%
Op Margin
-
Net Debt
-$692.87M
Current Ratio
7.41
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology